Candice Davison Shares a Review on Kell and Kx Blood Group Systems
Candice Davison, Project Research Scientist – Genomics Transfusion Array at Australian Red Cross Lifeblood, shared on LinkedIn:
”Excited to share a recent collaboration with my mentor Dr. Gregory A. Denomme—our review on the Kell (ISBT 006) and Kx (ISBT 019) blood group systems is now published in Immunohematology!
Since 2015, these systems have expanded significantly, with new antigens and alleles registered by ISBT.
Advances in molecular diagnostics are reshaping how we resolve serologic challenges and predict fetal blood type in alloimmunised pregnancies—critical for preventing HDFN.
Anti-K remains a key clinical concern, and emerging technologies like single-cell sequencing and gene editing are opening new doors to understanding red cell biology and immunogenicity.
Davison CL, Denomme GA. Kell and Kx blood group systems: an update. Immunohematology. 2025 Oct 31;41(3):90–99. doi: 10.2478/immunohematology-2025-014
Grateful for the opportunity to learn and contribute alongside a mentor who continues to shape the field!
Your guidance, insight, and generosity Greg, have made this collaboration deeply meaningful.”
Read the abstract here.
Stay updated with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia